Ected in melanoma 35 and non-small cell lung cancer (NSCL) sufferers.37 Release of NKG2DL in
Ected in melanoma 35 and non-small cell lung cancer (NSCL) sufferers.37 Release of NKG2DL in the cancer cell surface reduces their immunogenicity, thereby facilitating tumor progression. In B-cell CLL patients,…